Susquehanna Fundamental Investments’s BeOne Medicines Ltd ONC Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,718	Closed	-$1.48M	–	1131
2022 Q4	$1.48M	Sell	6,718 -3,328	-33%	-$610K	0.03%	563
2022 Q3	$1.35M	Buy	+10,046	New	+$1.73M	0.02%	702
2022 Q1	$1.9M	Buy	+10,046	New	+$2.14M	0.04%	604
2021 Q4	–	Sell	-5,670	Closed	-$2.06M	–	1803
2021 Q3	$2.06M	Buy	+5,670	New	+$1.85M	0.04%	589

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Susquehanna Fundamental Investments's ONC Position: Q1 2023 in Review

Susquehanna Fundamental Investments sold out of BeOne Medicines Ltd (ONC) in Q1 2023, closing a stake of 6,718 shares — an estimated $1.48M sold.

Susquehanna Fundamental Investments first reported a position in ONC in Q3 2021 and held it in 4 quarters. The position peaked at $2.06M in Q3 2021. 220 funds tracked by Wall St. Rank hold ONC as of Q1 2023.

Susquehanna Fundamental Investments reported no remaining BeOne Medicines Ltd position as of Q1 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 6,718 BeOne Medicines Ltd shares in Q1 2023, an estimated $1.48M.
Susquehanna Fundamental Investments first reported a position in BeOne Medicines Ltd in Q3 2021 and held it in 4 quarters.
Susquehanna Fundamental Investments's BeOne Medicines Ltd position peaked at $2.06M in Q3 2021.
220 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2023, filed 16 May 2023.